Neuren Pharmaceuticals Ltd has released a press release.
Q2 2020 Activity Report and Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Proposed issue of Securities - NEU
- Neuren successfully completes $20m capital raising
- Temporary enrolment pause ended in Phase 3 trial in the US
- Neuren announces changes to leadership team
- Neuren commences first clinical trial for NNZ-2591
Later from Neuren Pharmaceuticals
- Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
- Quarterly report and cash flow statement for Q3 2020
- Approval received for final stage of NNZ-2591 clinical trial
- Positive opinion for all 3 Orphan applications in Europe
- European Commission grants 3 NNZ-2591 Orphan designations
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals